COMP <GO>
HXL vs BCPC // EV/EBITDA & P/E VALUATION
Hexcel Corporation (NYSE) VS. Balchem Corporation (NASDAQ) • 15-METRIC TALLY: HXL 2
— BCPC 11
▲ EV/EBITDA & P/E VALUATION LEADER: BCPC
LAST: $79.55 (+1.97%) • MKT CAP: $6.02B
valuation
29.7x
LAST: $170.40 (+2.47%) • MKT CAP: $5.41B
valuation
25.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HXL VS. BCPC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HXL | BCPC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.00% | 35.70% | -12.70 | BCPC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.20% | 14.00% | -7.80 | BCPC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 29.7x | 25.5x | +4.20 | BCPC | /valuation <GO> |
| Free Cash Flow Yield | 2.61% | 4.00% | -1.39 | BCPC | /fcf-yield <GO> |
| Operating Margin | 9.10% | 20.20% | -11.10 | BCPC | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 14.90% | -9.10 | BCPC | /net-margins <GO> |
| Revenue Growth (YoY) | -0.50% | 8.80% | -9.30 | BCPC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.90% | 0.52% | +0.38 | HXL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.77 | 9.67 | -4.90 | BCPC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | BCPC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.9 | 50.4 | -13.53 | BCPC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | 32.6x | +18.60 | BCPC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.02B | $5.41B | $607.2M | HXL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HXL REV | BCPC REV | HXL GROSS % | BCPC GROSS % | HXL FCF | BCPC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.89B | $1.04B | 23.0% | 35.7% | $157.2M | $216.6M |
| FY 2024 | $1.90B | $953.7M | 24.7% | 35.3% | $202.9M | $182.0M |
| FY 2023 | $1.79B | $922.4M | — | — | $176.6M | $183.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HXL // BETA 1.02
BCPC // BETA —